New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
05:48 EDTCLVSClovis CO-1686 shows compelling clinical activity, PFS in updated Phase 1 study
Clovis Oncology announced updated findings from the Phase 1 portion of its ongoing Phase 1/2 clinical study of CO-1686, the company’s novel, oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor, or EGFR, for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. In the 22 evaluable T790M positive patients across efficacious dose levels, 14 RECIST partial responses, or PRs, have been observed to date, for a 64% objective response rate, or ORR. Ten of the 14 patients started CO-1686 therapy immediately following progression on a prior TKI. Twenty of the 22 evaluable T790M positive patients, or 91%, have experienced stable disease or a PR. The median duration of response cannot yet be estimated in the T790M positive patients. However, progression-free survival, or PFS, greater than six months has been observed in evaluable T790M positive heavily-pretreated patients and the median has not yet been reached. In contrast, PFS in T790M negative patients is shorter, with a median of three months. CO-1686 is well-tolerated, with only one patient who discontinued treatment with CO-1686 due to adverse events. There was no evidence of systemic wild-type EGFR inhibition. The most common adverse events were hyperglycemia, nausea, diarrhea, decreased appetite and vomiting, and these were mostly grade 1 in severity. The most common grade 3 adverse event was hyperglycemia, which was observed in 19% of patients. Hyperglycemia, when observed and requiring treatment, is typically asymptomatic and managed with a commonly prescribed single oral agent.
News For CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
06:02 EDTCLVSClovis pullback on Astra data a buying opportunity, says Mizuho
Subscribe for More Information
April 13, 2015
16:21 EDTCLVSOn The Fly: Top stock stories for Monday
Subscribe for More Information
10:15 EDTCLVSHigh option volume stocks
Subscribe for More Information
10:00 EDTCLVSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:20 EDTCLVSOn The Fly: Pre-market Movers
HIGHER: Builders FirstSource (BLDR), up 54.35% after acquiring ProBuild in all-cash transaction... Arrowhead (ARWR), up 14.3% after being cleared to proceed with multiple dose Phase 2b study of ARC-520... Oramed Pharmaceuticals (ORMP), up 6.9% after enrolling first patient in glucose clamp study for oral insulin... Clovis Oncology (CLVS), up 8.2% after being upgraded to Buy from Neutral at Goldman... Quantum (QTM), up 3.2% after announcing go-to-market partnership with Dot Hill Systems (HILL)... Netflix (NFLX), up 3.4% after being upgraded to Buy from Neutral at UBS... Apple (AAPL), up just under 1% following reports of Apple Watch orders. LOWER: Sina (SINA), down 3% following a report from the Financial Times that China may shut down the company if censorship doesn't improve... Ruckus Wireless (RKUS), down 2.9% after being downgraded to Buy from Conviction Buy at Goldman... Allot Communications (ALLT), down 2.7% after being downgraded to Hold from Buy at Needham.
06:43 EDTCLVSClovis upgraded to Buy from Neutral at Goldman
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use